HR Execs on the Move

PharMerica

www.pharmerica.com

 
Headquartered in Louisville, Kentucky, with nearly $2 billion in annual revenues, PharMerica is one of the largest and fastest growing institutional pharmacy companies in America. We are a premier pharmacy services provider dedicated to providing innovative solutions for customers and patients. At PharMerica, you can choose your career path – hospital pharmacy, long term care pharmacy, corporate and non-clinical opportunities. We employ some of the industry`s best and brightest innovators and clinicians. With more than 100 long-term care pharmacies in over 45 states nationwide, PharMerica employs approximately 5,500 dedicated employees and pharmacy professionals. We offer our staff the opportunity to ...
  • Number of Employees: 1K-5K
  • Annual Revenue: > $1 Billion

Executives

Name Title Contact Details

Similar Companies

Physician Partner

Physician Partner is a Newbury Park, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Predictive Oncology

Updates, earnings and commercializationListen to the audio recording of our recent shareholder call where we discussed the latest updates, gave an overview of our earnings report and highlighted the commercialization efforts underway at Predictive Onco...

Sol-Millennium Medical Group

SOL-MILLENNIUM is a vertically integrated global medical supply company with locations across the globe. We are one of the worlds largest manufacturers of needles, syringes, and blood collection devices with a comprehensive line of medical supplies fo...

Noven

Noven Pharmaceuticals, Inc. is a dynamic specialty pharmaceutical company engaged in the research, development, manufacture, marketing and sale of prescription pharmaceutical products. We are committed to developing and offering pharmaceutical products that meaningfully benefit patients, with a commitment to advancing patient care through transdermal drug delivery.

Cyteir

Cyteir is a clinical-stage oncology company that is focused on the discovery and development of next-generation synthetically lethal therapies to treat cancer. The company is using its expertise in DNA damage response biology to advance a pipeline of novel drug candidates that selectively target key cancer vulnerabilities. Cyteir`s wholly owned lead compound, CYT-0851, is a potent and selective, oral investigational drug currently in a Phase 1/2 clinical trial for hematologic and solid tumors.